Markets
E.l.f. beauty shares rip after it receives market upgrade
(Michael M. Santiago/Getty Images)

e.l.f Beauty rips after Morgan Stanley upgrade

The market is too worried about the cosmetic company’s price hikes, the analysts say.

Matt Phillips
8/11/25 1:18PM

Cosmetics company e.l.f. Beauty jumped Monday after Morgan Stanley upgraded its rating on the stock to “over-weight” from “equal-weight” and raised its price target to $134 from $114.

Despite reporting results that more or less beat Wall Street expectations last week, e.l.f. saw its share price plunge as executives sounded less than certain that consumers would swallow the large price hikes the company is putting in place this month to offset tariff-related costs.

“With these increases just going in on August 1, we’re still reading how the consumer will respond to that,” e.l.f. CEO Mandy Fields told analysts. “It will take a couple of weeks for that to fully roll out within retail. And so that is something that we’re watching for.”

e.l.f. shares fell 9.5% the next day. But with a few days of perspective, Morgan Stanley analysts led by Dara Mohsenian have decided the market, basically, got it wrong. In a note published Monday, they wrote:

“We Believe Bear Concerns on Pricing Demand Elasticity Risk Are Overblown: ELF implemented a 14% weighted price increase on August 1... Bear worries on pricing stem from a few areas: a) low income consumers are under severe pressure in the US to begin with, so any ELF price increases could drive a large demand reaction, b) ELF has never taken such a large magnitude of price increases across its portfolio, and c) ELF has never taken pricing across its entire portfolio at once. Thus, we believe the market/consensus is currently assuming a sizeable demand elasticity response to ELF’s price increase.”

Morgan Stanley argues that’s wrong for a few reasons. One, they said, is that consumers tend to be not especially sensitive to the pricing of beauty products they use, “given the relative importance of beauty products to consumers.”

They added that e.l.f. cosmetics are already pretty cheap compared to other options, meaning there’s less opportunity for consumers to find more affordable substitutes.

The analysts also looked to the experience of consumer packaged goods companies during the 2022 inflationary period, when many companies pushed substantial price increases. The takeaway from that experience, the analysts wrote, is that sales volumes tended to react more or less similarly to small or large price increases.

In other words, while companies did lose some sales because of big price increases, sales didn’t decline anywhere near as much as prices increased. Thus companies were able to recoup any lost sales by charging more. And that’s a big part of the reason why US corporate profit surged at the time.

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.